Melanoma trials in Czechia

In Czechia 8 Also abroad 578

8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Brno, Prague
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
No phaseTaking people
Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care
Where
Brno, Olomouc, Pilsen, Prague
Age
50 years and over
People
1,440
Run by
Institute of Health Information and Statistics of the Czech Republic
See details and how to joinNCT07349940
No phaseTaking people
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
Where
Brno
Age
18 years and over
People
17
Run by
Masaryk Memorial Cancer Institute
See details and how to joinNCT07870265
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Brno-Stred, Novy Hradec Kralove, Olomouc
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 3Taking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Hradec Králové
Age
18 years to 70 years
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
Phase 3Enrolling by invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
Where
Plzen 23, Prague, Prague 6
Age
18 years and over
People
100 worldwide
Run by
Aura Biosciences
See details and how to joinNCT07338968 · EU 2025-524405-33-00
Phase 3Taking people
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Where
Prague 6
Age
18 years and over
People
520 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00
Phase 3Taking people
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Where
Hradec Králové, Olomouc, Prague
Age
18 years and over
People
680 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT06112314